NCT04014205 2023-04-18A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesBeijing InnoCare Pharma Tech Co., Ltd.Phase 1/2 Unknown81 enrolled